Tuesday, September 29, 2020 7:41:18 AM
Om, take a deep breath brother! Slow down and wait until you hear from the company about Nasdaq.
As far as the DSMB, if they don’t stop the trial (most likely will not), the Trial should be fully enrolled by end of the year. Remember it’s a phase 3...
In my experience (take it for what it’s worth), when people let emotions get involved when dealing with stocks it’s almost always a mistake. Remember that 99% of what you read on this board is nonsensical. Most is not even true. This is a penny stock message board...
If you have questions about “unpaid bills” or any other nonsense, ask the company, they are quite responsive.
Remember, every person on this board has a motive, whether that is hold this long, sell it short, swing it, or day trade it..
From your past posts, I believe you are a long... if that’s the case, just hang on my man and drown out the noise. Don’t worry about the stock price each day, focus on where you believe it will be in a year. If you believe it’s going to be “X” in a years period of time it doesn’t matter tomorrow if it’s $6 or $1....
Have a great day Om!
As far as the DSMB, if they don’t stop the trial (most likely will not), the Trial should be fully enrolled by end of the year. Remember it’s a phase 3...
In my experience (take it for what it’s worth), when people let emotions get involved when dealing with stocks it’s almost always a mistake. Remember that 99% of what you read on this board is nonsensical. Most is not even true. This is a penny stock message board...
If you have questions about “unpaid bills” or any other nonsense, ask the company, they are quite responsive.
Remember, every person on this board has a motive, whether that is hold this long, sell it short, swing it, or day trade it..
From your past posts, I believe you are a long... if that’s the case, just hang on my man and drown out the noise. Don’t worry about the stock price each day, focus on where you believe it will be in a year. If you believe it’s going to be “X” in a years period of time it doesn’t matter tomorrow if it’s $6 or $1....
Have a great day Om!
Recent CYDY News
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 01:35:02 PM
- CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab • GlobeNewswire Inc. • 03/05/2026 01:30:00 PM
- CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference • GlobeNewswire Inc. • 02/20/2026 01:30:00 PM
- CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer • GlobeNewswire Inc. • 01/27/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/09/2026 10:15:22 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/09/2026 01:30:45 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/22/2025 10:15:23 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/17/2025 05:15:14 AM
- December 2025 Letter to Shareholders • GlobeNewswire Inc. • 12/16/2025 01:30:00 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 12/10/2025 10:16:32 PM
- CytoDyn to Showcase PD-L1 Upregulation and Improved Survival in Metastatic Triple Negative Breast Cancer at the San Antonio Breast Cancer Symposium • GlobeNewswire Inc. • 12/08/2025 01:30:00 PM
